Pearl Steinzor

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.

Thomas Hall, MD, FAAD, of US Dermatology Partners, explains that disparities in dermatological care arise from the uneven distribution of dermatologists, especially in rural areas, causing delayed diagnoses and higher health care costs.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

Hrayr Attarian, MD, professor of neurology, Northwestern Feinberg School of Medicine, shares findings on sleep inequities that have greatly impacted refugees.

Caitlin Kindberg, patient advocate in Nashville, Tennessee, discusses her lived experience as an individual with idiopathic hypersomnia, and how the sleep disorder impacts her day-to-day life.

Expansion of Medicaid coverage will now include all-in-one mental health and substance use clinics; 61% of adults are estimated to have cardiovascular disease (CVD) by 2050; the FDA has taken a historic step in potential psychedelic drug approval.

Christopher Depner, PhD, professor of health and kinesiology, University of Utah, shares the challenges of measuring sleep with wearable devices due to nonadherence and the need for metrics like the Sleep Regularity Index.

Black children with asthma are disproportionately exposed to asthma triggers and access barriers, according to one study.

Shawn Kwatra, MD, dermatologist, John Hopkins University, recounts his study assessing the use of nemolizumab in prurigo nodularis presented at the American Academy of Dermatology conference.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, shares findings on the use of a novel treatment for patients with moderate to severe asthma.

Melissa B. Jones, MD, staff neuropsychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine, shares what she is looking forward to at this year's SLEEP 2024 conference.

Posters presented at the American Thoracic Society (ATS) 2024 International Conference examined factors of the pandemic that may have influenced the clinical presentation and diagnosis of respiratory symptoms, as well as health care resource utilization for serious asthma outcomes.

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE).

Psychological well-being should be considered in the management of psoriasis, research indicates.

Patients struggle to afford glucagon-like peptide-1 (GLP-1) medications for diabetes; doctors see potential and pitfalls in new ChatGPT model’s humanlike conversations; Medicare payment reform efforts focus on inflation adjustments and payment model overhauls.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, shares 3 key recommendations to improve the accuracy and quality of drug pricing data.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses ways to overcome barriers in clinical trials for diverse patients with psoriasis.

Underlying mood and sleep disorders may negatively affect asthma control, researchers find.

Researchers compare treatments and outcomes in patients with Sydenham chorea, finding faster resolution with corticosteroid treatment.

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.

Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.

Session speakers at the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research share their favorite parts of the conference.

Asking patients about their diet is important when evaluating for adult-onset asthma, allergic disease, and aspirin-exacerbated respiratory disease (AERD).

Phaedra Corso, PhD, associate vice president for research, Indiana University, discusses the importance of cost-effectiveness analysis in determining the feasibility and impact of public health interventions.

William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits and advancements of cost-effectiveness analysis to improve decision-making and efficiency.

Nancy Dreyer, PhD, MPH, FISE, chief scientific advisor to Picnic Health, shares some of the ways that direct-to-patient approaches have improved observational research.

Kimberly Westrich, MA, of the National Pharmaceutical Council, explains how the 340B program is linked to increased drug spending and the hidden costs associated with it.